Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 10/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5857667 | 0.92 | CTSL (0.44) | FOLH1ALBCTSLCA2CA12 | |
| SCHEMBL5858508 | 0.90 | TGM2 (0.45) | FOLH1CA2CA12CA1CA9 | |
| SCHEMBL5857654 | 0.90 | ALB (0.46) | FOLH1ALBCA2CA12CA1 | |
| SCHEMBL5857630 | 0.90 | ITGB3 (0.47) | CA2CA12CA1CA9 | |
| SCHEMBL5856010 | 0.90 | ITGB3 (0.47) | CA2CA12CA1CA9 | |
| SCHEMBL5858377 | 0.90 | ITGB3 (0.47) | CA2CA12CA1CA9 | |
| SCHEMBL5855784 | 0.89 | GRN (0.46) | FOLH1ALBCA2CA12CA1 | |
| SCHEMBL5855896 | 0.82 | CTSL (0.41) | FOLH1ALBCTSLALDH1A1HPGD | |
| SCHEMBL5855147 | 0.82 | NR1H4 (0.41) | CA2CA12CA1CA9ALDH1A1 | |
| SCHEMBL5857551 | 0.82 | PPARG (0.40) | ALBCA2CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144906-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-12-05 | — | — | US | disclosed |
| US-7030143-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-7022723-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1634876-A2 | Heterocyclic compounds for the treatment of hyperlipidemia agents | Nippon Shinyaku Co., Ltd. (JP) | 2006-03-15 | — | — | EP | disclosed |
| US-6998412-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-02-14 | — | — | US | disclosed |
| US-20050009892-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20050009785-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040162325-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2004-08-19 | — | — | US | disclosed |
| US-20030166697-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1295875-A1 | HETEROCYCLIC COMPOUNDS | Nippon Shinyaku Co., Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009785-A1 | Heterocyclic compounds | LIPC, GPR119, APOB | FOLH1 2019/4885ALB 631/4885CTSL 3295/4885 |
| US-20050009892-A1 | Heterocyclic compounds | GPR119, LIPC, LIPE | FOLH1 2679/4885ALB 1124/4885CTSL 3334/4885 |
| US-20040162325-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | FOLH1 2827/4885ALB 1460/4885CTSL 3811/4885 |
| US-20030166697-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | FOLH1 2827/4885ALB 1460/4885CTSL 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.